Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial
Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial
复制标题
DOI:
10.1007/s00431-002-0915-y
复制
发表时间:
2002-04-01
影响因子:
3.6
通讯作者:
Saia, OS
中科院分区:
文献类型:
--
作者:
Lago, P;Bettiol, T;Saia, OS
Indomethacin (INDO) and, more recently, ibuprofen (IBU) have been used to treat haemodynamically significant patent ductus arteriosus (PDA) in preterm infants. Both are cyclo-oxygenase blockers, but seem to have a different influence on regional circulation. In a prospective, randomised, controlled study, we compared INDO and IBU with regard to efficacy and safety for the early non-invasive treatment of PDA. Doppler echocardiography was used to study 232 preterm infants (gestational age 23-34 weeks) with respiratory distress syndrome of whom 175 had persistent, haemodynamically significant PDA at 48-72 h of life. They were randomised to receive three intravenous doses of either INDO (0.2 mg/kg, at 12 h intervals) or IBU (a first 10 mg/kg dose followed by two doses of 5 mg/kg at 24 h intervals), recording rate of ductal closure, need for additional treatment, side-effects and clinical course. The efficacy of the pharmacological treatment was similar in the two groups (56/81, 69% INDO; 69/94, 73% IBU). Patients treated with INDO showed a significant increase in serum creatinine (89+/-24 versus 82+/-20 mmol/l, P=0.03) and a near-significant tendency for a lower fractional excretion of sodium (3+/-3 versus 4+/-2%, P = 0.08); moreover. 12/81 (15%) INDO patients versus 1/94 (1%) IBU patients became oliguric (